Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for Hard-to-Treat cancers: ABX-001 enters human trials

NCT ID NCT07231458

First seen Nov 17, 2025 · Last updated May 19, 2026 · Updated 26 times

Summary

This early-phase study tests a new drug called ABX-001, given alone or with an immunotherapy (pembrolizumab), in adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check safety and find the best dose. About 27 participants will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Charite-Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF)

    RECRUITING

    Berlin, 12200, Germany

  • Hospital Universitario Fundacion Jimenez Diaz

    RECRUITING

    Madrid, 28040, Spain

  • The START Center for Cancer Care - CIOCC

    RECRUITING

    Madrid, 28050, Spain

  • Universitaetsklinikum Tuebingen

    RECRUITING

    Tübingen, 72076, Germany

  • Vall d'Hebron Institut d'Oncologia

    RECRUITING

    Barcelona, 08035, Spain

Conditions

Explore the condition pages connected to this study.